Tg Therapeutics (TGTX) Long-Term Investments (2013 - 2026)

Tg Therapeutics' Long-Term Investments history runs 9 years deep, the most recent figure standing at $61.5 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 3126.95% year-over-year to $61.5 million in Q1 2026; TTM through Mar 2026 was $61.5 million, a 3126.95% increase from a year earlier, with the FY2025 full-year figure at $59.1 million, up 7218.81% from the prior year.
• Long-Term Investments improved to $61.5 million in Q1 2026 per TGTX's latest filing, from $59.1 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $61.5 million in Q1 2026 and bottomed at $808000.0 in Q4 2024.
• The 4-year median for Long-Term Investments is $21.8 million (2022), against an average of $24.8 million.
• Across the five-year window, Long-Term Investments sank 65.09% in 2022 and soared 7218.81% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $12.4 million in 2022, then sank by 93.49% to $808000.0 in 2024, then surged by 7218.81% to $59.1 million in 2025, then grew by 4.06% to $61.5 million in 2026.
• Per Business Quant, the three latest TGTX Long-Term Investments figures stand at $61.5 million (Q1 2026), $59.1 million (Q4 2025), and $48.8 million (Q3 2025).